(Q35169057)

6 August 2017

1 reference

title

Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma (English)

1 reference

6 August 2017

Laura K Hummers

1

1 reference

PubMed ID

12841296

6 August 2017

Fredrick M Wigley

series ordinal

2

1 reference

6 August 2017

1 May 2003

1 reference

Rheumatic Diseases Clinics of North America

6 August 2017

1 reference

6 August 2017

29

1 reference

6 August 2017

2

1 reference

6 August 2017

293-313

1 reference

Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Total and nutritional blood flow in the finger

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Total and Capillary Fingertip Blood Flow in Raynaud's Phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Assessment of vascular function in systemic sclerosis: Indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

The post-occlusive hyperemic response in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

The effect of simple warming procedures on finger blood flow in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Prevalence of Raynaud's phenomenon in a healthy Greek population

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Interferon-alpha induced Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

The effect of transdermal nicotine on digital perfusion in reformed habitual smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Raynaud's phenomenon: epidemiology and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Association between cigarette and alcohol consumption and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Once daily felodipine in patients with primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

The clinical effect of felodipine and nifedipine in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

The treatment of severe Raynaud's phenomenon with verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Three cases of digital ischemia successfully treated with cilostazol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Successful treatment of Raynaud's phenomenon with pentoxifylline

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Subjective and objective assessment of enalapril in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Enalapril in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Vascular remodeling: the role of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Thoracoscopic cervicodorsal sympathectomy: preliminary results.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Transthoracic endoscopic sympathectomy for hyperhidrosis and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Sympathectomy for Raynaud's phenomenon; follow-up study of 70 women with Raynaud's disease and 54 women with secondary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Digital artery sympathectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Radical microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Limited microsurgical arteriolysis for complications of digital vasospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900019-X

7 January 2021

10.1016/S0889-857X(03)00019-X

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12841296